Kura Oncology, Inc. (KURA)
After hours:
- Zacks
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
The consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Kura Oncology to Host Investor Event on December 10, 2022
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New OrleansSAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will host an investor event featuring members of the Kura management team and investigators from KOMET-001, a Phase 1/2 clinical trial of ziftomenib, the Compan
- Zacks
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
